IL-32 as a potential biomarker and therapeutic target in cardiovascular disease

Cardiovascular diseases remain a leading cause of death worldwide, driven by complex pathological mechanisms involving various cytokines and inflammatory responses. IL-32, a recently discovered cytokine, has emerged as a key player in the pathogenesis of cardiovascular diseases, including atherosclerosis, myocardial infarction, and heart failure. This review summarizes the biological characteristics of IL-32 and its role in cardiovascular diseases, explores its involvement in inflammatory responses and other pathological processes, and evaluates its potential as both a biomarker and a therapeutic target. Collectively, this review aims to provide new insights for the prevention and treatment of cardiovascular diseases.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-04-22
DOI
https://doi.org/10.3389/fimmu.2026.1755759
Primary Topic
Cytokine Signaling Pathways and Interactions
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

IL-32 as a potential biomarker and therapeutic target in cardiovascular disease

Qingwei Ji, Jing Ye, Lingyue Qiu, Ling Liu
Frontiers in Immunology
Cytokine Signaling Pathways and Interactions
article

IL-32 as a potential biomarker and therapeutic target in cardiovascular disease

Qingwei Ji, Jing Ye, Lingyue Qiu, Ling Liu
article en

Abstract

Cardiovascular diseases remain a leading cause of death worldwide, driven by complex pathological mechanisms involving various cytokines and inflammatory responses. IL-32, a recently discovered cytokine, has emerged as a key player in the pathogenesis of cardiovascular diseases, including atherosclerosis, myocardial infarction, and heart failure. This review summarizes the biological characteristics of IL-32 and its role in cardiovascular diseases, explores its involvement in inflammatory responses and other pathological processes, and evaluates its potential as both a biomarker and a therapeutic target. Collectively, this review aims to provide new insights for the prevention and treatment of cardiovascular diseases.

Frontiers in ImmunologyVol. 17
Wuhan University (CN), The People's Hospital of Guangxi Zhuang Autonomous Region (CN), Renmin Hospital of Wuhan University (CN)
National Natural Science Foundation of China
Good health and well-being
Openalex Percentile: Top 22%
Cytokine Signaling Pathways and Interactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

IL-32 as a potential biomarker and therapeutic target in cardiovascular disease — Qingwei Ji, Jing Ye, et al. · Frontiers in Immunology (2026) | TGRS Research Map | TGRS